Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment: latest news

Hepatitis C treatment resources

  • Hepatitis C treatment

    Effective direct-acting antiviral or 'DAA' medicines, used without interferon, can now cure most people with hepatitis C. This includes people who previously were considered to be more difficult...

    From: Booklets

    Information level Level 2
  • Medications for hepatitis C

    DAAs target different steps of HCV reproduction. These include HCV protease inhibitors, polymerase inhibitors and NS5A inhibitors. Recommended regimens include at least two drugs that work in different...

    From: Booklets

    Information level Level 2
  • Treatment for people with HIV and HCV co-infection

    In the UK, standards for HIV treatment and care are set and monitored by the British HIV Association (BHIVA), the professional association for HIV doctors and other healthcare...

    From: Booklets

    Information level Level 2
  • Hepatitis C and HIV

    Hepatitis C is a blood-borne infection that is transmitted in some of the same ways as HIV.Over time untreated hepatitis C...

    From: Factsheets

    Information level Level 2
  • Hepatitis C

    Hepatitis C is a serious infection caused by a virus.It damages the liver, which performs essential functions in the body.Some people have hepatitis C for...

    From: The basics

    Information level Level 1

Hepatitis C treatment features

Hepatitis C treatment in your own words

Hepatitis C treatment news from aidsmap

More news

Hepatitis C treatment news selected from other sources

  • Rwanda launches 5-year campaign to eradicate hepatitis C

    Rwanda on Tuesday launched a five-year plan to detect and treat hepatitis C virus as part of a campaign that aims at eliminating hepatitis C in the country.

    12 December 2018 | Xinhua
  • Moving on with my life: Getting cured of hepatitis C

    Interviews with people who have had successful treatment for hepatitis C & what it means for them. Made for the annual conference of the London Joint Working Group on Substance Use & Hepatitis C, Held at The Guildhall London on 3 December 2018.

    07 December 2018 | YouTube
  • Eliminating Hepatitis: A unique opportunity that shouldn't be missed

    Micro-elimination seeks to eliminate HCV in particular target populations, permitting rapid, focused action. It can also address inequities in service delivery by concentrating health system attention on stigmatised groups. Initiatives aimed at specific risk groups, such as men who have sex with men, migrants and drug users, already exist for HIV in so-called ‘Fast-Track’ cities, such as Amsterdam and Madrid and need to be adapted to include hepatitis.

    22 November 2018 | The Parliament Magazine
  • Vosevi safe, effective in ‘triple-infected’ patients with HCV, HBV, HIV

    The direct-acting antiviral Vosevi demonstrated an average sustained virologic response rate of 87% among patients who were “triple-infected” with hepatitis C genotype 3, hepatitis B and HIV, as presented at the American College of Gastroenterology Annual Meeting.

    15 October 2018 | Healio
  • Anti-virals cure up to 98% of hepatitis C patients since 2014

    The figures from the national treatment registry for Irish hepatitis C patients represent “a triumph of science”, Dr Diarmuid Houlihan, a hepatologist at St Vincent’s University Hospital told a conference in Dublin on Monday.

    09 October 2018 | Irish Times
  • What It Means for Gilead to Launch Its Own Generics for Hepatitis C Treatments

    There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large drug and biotech companies have done so in recent years, and this is what is being seen at Gilead Sciences Inc.

    25 September 2018 | 24/7 Wall St.
  • Gilead to launch generic versions of its hepatitis drugs

    Gilead Sciences Inc said on Monday it plans to launch generic versions of its hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

    25 September 2018 | Reuters
  • Brazil court strips Gilead hepatitis drug patent, politician says

    A Brazilian court has stripped the patent protection of a Gilead Sciences Inc big-selling hepatitis C treatment in Brazil, paving the way for cheaper generics, a presidential candidate who pushed for the move said on Monday.

    25 September 2018 | Reuters
  • Overwhelming evidence shows hepatitis C treatment effective for people who inject drugs

    Researchers are calling on an end to discriminatory health and illicit drugs policies, based on overwhelming evidence that new hepatitis C therapies are effective at curing the virus in people who inject drugs.

    21 September 2018 | EurekAlert
  • EPO Upholds Gilead Patent On Hep C Medicines, But In Amended Form

    The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained in an amended form. Civil society involved in the case expressed dismay over the outcome and its potential effect on European drug prices.

    16 September 2018 | Intellectual Property Watch
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.